Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of EBITDA Margin data on record, last reported at 5.46% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2960.0% year-over-year to 5.46%; the TTM value through Dec 2025 reached 14.67%, up 4839.0%, while the annual FY2025 figure was 14.67%, 4839.0% up from the prior year.
  • EBITDA Margin reached 5.46% in Q4 2025 per TARS's latest filing, up from 10.39% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 31.04% in Q1 2021 and bottomed at 4393.79% in Q4 2021.
  • Average EBITDA Margin over 5 years is 735.52%, with a median of 64.72% recorded in 2024.
  • The widest YoY moves for EBITDA Margin: up 425716bps in 2022, down -378577bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 4393.79% in 2021, then soared by 97bps to 136.63% in 2022, then crashed by -135bps to 320.4% in 2023, then surged by 89bps to 35.06% in 2024, then surged by 84bps to 5.46% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 5.46% in Q4 2025, 10.39% in Q3 2025, and 19.86% in Q2 2025.